RhumbLine Advisers’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-1,441
| Closed | -$98K | – | 3304 |
|
|
2022
Q1 | $98K | Buy |
1,441
+244
| +20% | +$16.6K | ﹤0.01% | 2889 |
|
|
2021
Q4 | $145K | Buy |
1,197
+15
| +1% | +$1.82K | ﹤0.01% | 2892 |
|
|
2021
Q3 | $166K | Buy |
1,182
+51
| +5% | +$7.16K | ﹤0.01% | 2938 |
|
|
2021
Q2 | $311K | Buy |
1,131
+151
| +15% | +$41.5K | ﹤0.01% | 2770 |
|
|
2021
Q1 | $210K | Buy |
980
+11
| +1% | +$2.36K | ﹤0.01% | 2820 |
|
|
2020
Q4 | $234K | Buy |
969
+109
| +13% | +$26.3K | ﹤0.01% | 2771 |
|
|
2020
Q3 | $91K | Sell |
860
-29
| -3% | -$3.07K | ﹤0.01% | 2883 |
|
|
2020
Q2 | $87K | Sell |
889
-127
| -13% | -$12.4K | ﹤0.01% | 2983 |
|
|
2020
Q1 | $76K | Hold |
1,016
| – | – | ﹤0.01% | 2824 |
|
|
2019
Q4 | $83K | Buy |
1,016
+14
| +1% | +$1.14K | ﹤0.01% | 2889 |
|
|
2019
Q3 | $122K | Buy |
1,002
+71
| +8% | +$8.65K | ﹤0.01% | 2855 |
|
|
2019
Q2 | $167K | Buy |
931
+171
| +23% | +$30.7K | ﹤0.01% | 2835 |
|
|
2019
Q1 | $122K | Buy |
+760
| New | +$122K | ﹤0.01% | 2835 |
|